According to DelveInsight, the market size of Pulmonary Arterial Hypertension in 7MM was found to be USD 4.6 Billion in 2017.
Among the 7MM, the United States accounts for the largest market size of Pulmonary Arterial Hypertension, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
The total number of prevalent cases of Pulmonary Arterial Hypertension (PAH) in 7MM was found to be 70,774, in the year 2017.
The key players in the Pulmonary Arterial Hypertension market include United Therapeutics Corporation, Liquidia Technologies, Reata Pharmaceuticals, Altavant Sciences, Acceleron Pharma, PhaseBio Pharmaceuticals, Complexa, Arena Pharmaceuticals, Johnson & Johnson, GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc., Bayer AG, Pfizer, Bellerophon Pulse Technologies, and many others.
For more information visit:
https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pah-market#infographics